Clinical Trials on Coagulation Defect in Japan

Total 194 results

Kyowa Kirin Co., Ltd.

Completed

A Clinical Study of KW-3357 in Patients With DIC (3357-005)

Disseminated Intravascular Coagulation (DIC)

Japan
Kyowa Kirin Co., Ltd.

Terminated

A Phase 3 Clinical Study of KW-3357 in Patients With DIC (3357-006)

Disseminated Intravascular Coagulation (DIC)

Japan
Kyowa Kirin Co., Ltd.

Completed

An Open-label Study of KW-3357 (3357-004)

Disseminated Intravascular Coagulation (DIC)

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Persistent Corneal Epithelial Defect

Japan
Takeda

Completed

A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.

Hemophilia A

Japan
Asahi Kasei Pharma Corporation

Completed

Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment

Disseminated Intravascular Coagulation

Japan
Bayer

Active, not recruiting

Drug Use Investigation of Kovaltry in Hemophilia A Patients

Hemophilia A

Japan
Nara Medical University
Shire

Unknown

Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors

Hemophilia A With Inhibitor

Japan
Pfizer

Completed

BeneFIX Drug Use Results Survey [All-Case Surveillance]

Hemophilia B

Japan
Bayer

Active, not recruiting

An Observational Study to Learn About the Occurrence of Disseminated Intravascular Coagulation Among Adults With Sepsis in Japan

Sepsis | Disseminated Intravascular Coagulation

Japan
Novo Nordisk A/S

Enrolling by invitation

Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors

Haemophilia A | Haemophilia B

Japan
Novo Nordisk A/S

Completed

Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

Japan
Novo Nordisk A/S

Completed

Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

Japan
Novo Nordisk A/S

Completed

Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

Japan
Abbott Medical Devices

Active, not recruiting

Amplatzer PFO Occluder Post-marketing Surveillance Study (PFO PMS Jpn)

PFO - Patent Foramen Ovale

Japan
Novo Nordisk A/S

Completed

To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan

Congenital Bleeding Disorder | Haemophilia A

Japan
Population Health Research Institute
The Hospital for Sick Children

Completed

Tetralogy of Fallot for Life (TOF-LIFE)

Tetralogy of Fallot | Congenital Heart Disease | Congenital Heart Defect

Canada, United States, Korea, Republic of, Australia, China, Japan, India, Indonesia, Nepal, Russian Federation, Saudi Arabia, Ukraine
Kiminori Kimura, MD
Japan Agency for Medical Research and Development; Ohara Pharmaceutical Co....

Completed

Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV With Hemophilia.

Liver Cirrhosis

Japan
BioMarin Pharmaceutical

Active, not recruiting

Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A (GENEr8-JPN)

Hemophilia A

Japan
Novo Nordisk A/S

Completed

A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan

Congenital Bleeding Disorder | Glanzmann's Disease

Japan
Baxalta now part of Shire
Baxter Innovations GmbH

Completed

BAX 855 Dose-Escalation Safety Study

Hemophilia A

Japan, Bulgaria, Germany, United Kingdom
Takeda

Active, not recruiting

A Study of TAK-662 for Japanese Patients With Congenital Protein C Deficiency

Congenital Protein C Deficiency

Japan
Novo Nordisk A/S

Completed

Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Spain, Germany, Japan
Taisho Pharmaceutical Co., Ltd.

Completed

A Food Effect Study of TS-142 in Healthy Subjects

Effect of Food

Japan
W.L.Gore & Associates

Recruiting

Japan Post Marketing Surveillance of the GORE® CARDIOFORM Septal Occluder (GSO-PFO PMS)

Stroke | TIA | Cryptogenic Stroke | PFO - Patent Foramen Ovale

Japan
Eli Lilly and Company

Completed

A Bioequivalence (BE) Study in Healthy Subjects

Attention Deficit Hyperactivity Disorder

Japan
Kiminori Kimura, MD
Japan Agency for Medical Research and Development

Recruiting

A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201)

Liver Cirrhosis

Japan
Eli Lilly and Company

Completed

Safety Study in Outpatient Japanese Children With ADHD

Attention Deficit Hyperactivity Disorder

Japan
Bayer

Completed

A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors

Hemophilia A | Hemophilia B

Ukraine, United Kingdom, Bulgaria, Germany, Japan
Novo Nordisk A/S

Enrolling by invitation

Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®

Haemophilia A

Japan
Novo Nordisk A/S

Completed

Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency

Congenital Bleeding Disorder | Congenital FVII Deficiency

Japan
Novo Nordisk A/S

Completed

Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers

Healthy | Congenital Bleeding Disorder

Japan
Takeda

Completed

Study of TAK-672 in Participants With Acquired Hemophilia A

Acquired Hemophilia A

Japan
Baxalta now part of Shire
Takeda

Completed

RIXUBIS Drug Use-Result Survey (Japan)

Hemophilia B

Japan
Chiba University

Completed

Tipepidine in Children With Attention Deficit/Hyperactivity Disorder (AD/HD): a Double-blind, Placebo-controlled Trial

Attention Deficit and Disruptive Behavior Disorders | Hyperkinesis | Attention Deficit Disorder With Hyperactivity Disease

Japan
Chiba University

Completed

An Open Study of Tipepidine Hibenzate in Patients With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity

Japan
Bayer

Completed

Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment (ECHO)

Hemophilia A

United States, Japan, United Kingdom, Spain
Novo Nordisk A/S

Completed

Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers

Healthy | Acquired Bleeding Disorder | Cardiac Surgery Requiring Cardiopulmonary Bypass

Japan
Bioverativ, a Sanofi company

Completed

A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

Hemophilia A

United States, Japan
Weill Medical College of Cornell University
Bayer; University Hospital, Bonn

Completed

Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study

Hemophilia A | Hemophilia B

United States, Israel, Australia, Italy, Sweden, Germany, Japan, Netherlands, Taiwan
Okayama University

Completed

Cardiac Biomarker in Pediatric Heart Disease

Congenital Heart Disease

Japan
Novo Nordisk A/S

Completed

A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543

Congenital Bleeding Disorder | Haemophilia A

Japan
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A (HAVEN 4)

Hemophilia A

United States, Belgium, Spain, Japan, Poland, Australia
Abbott Medical Devices
Japanese society of Congenital Interventional Cardiology

Recruiting

Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance

Patent Ductus Arteriosus

Japan
National Center of Neurology and Psychiatry, Japan

Completed

Cognitive Rehabilitation During Transcranial Direct Current Stimulation

Neurocognitive Disorders | Transcranial Direct Current Stimulation

Japan
Kurume University

Unknown

Pioglitazone Decreases Visceral Fat Metabolism

To Evaluate the Effect of Pioglitazone on Glucose Metabolism of Fat Tissue by Using FDG-PET/CT Imaging

Japan
Novo Nordisk A/S

Enrolling by invitation

Post-marketing Surveillance (Use Result Surveillance) With Refixia®

Haemophilia B

Japan, Denmark
Bayer

Terminated

Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors

Hemophilia A and B

Australia, United Kingdom, Taiwan, Japan, Korea, Republic of, Austria, Bulgaria, Hungary, Italy, France, New Zealand
Baxalta now part of Shire

Completed

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

Hemophilia A | Hemophilia B

Japan, Russian Federation, Spain, United States, Poland, Romania, Serbia, Taiwan, Ukraine
Okayama University
National Cerebral and Cardiovascular Center

Completed

Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single Ventricle Physiology (TICAP)

Heart Failure | Hypoplastic Left Heart Syndrome | Single Ventricle

Japan

Clinical Trials on Coagulation Defect in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations